Tata Memorial Hospital | |
---|---|
Geography | |
Location | Mumbai, Maharashtra, India |
Organisation | |
Funding | Government hospital |
Affiliated university | Homi Bhabha National Institute |
History | |
Founded | 28 February 1941 |
Links | |
Website | tmc.gov.in |
The Tata Memorial Hospital is situated in Parel, Mumbai in India. It is a specialist cancer treatment and research centre, closely associated with the Advanced Centre for Treatment, Research and Education in Cancer (ACTREC). One of the fields of specialization of this hospital is in the treatment of acute lymphoblastic leukemia (A.L.L). The hospital claims to treat and cure 99% of the A.L.L patients. This hospital is also one of the few in India to have a P.E.T. scanner. The Director of this hospital is Dr. Rajendra A Badwe, who took over from for director Dr. K.A. Dinshaw.
The Tata Memorial Centre is the national comprehensive cancer centre for the prevention, treatment, education and research in Cancer and is recognized as one of the leading cancer centres in this part of the world. This achievement has been possible due to the far-sighted and total support of the Department of Atomic Energy, under Dr. Homi N Sethna responsible for managing this Institution since 1962. The Tata Memorial Hospital was initially commissioned by the Sir Dorabji Tata Trust on 28 February 1941 as a center with enduring value and a mission for concern for the Indian people.
In 1952 the Indian Cancer Research Centre was established as a pioneer research institute for basic research—later called the Cancer Research Institute (CRI). In 1957 the Ministry of Health took over the Tata Memorial Hospital. The transfer of the administrative control of the Tata Memorial Centre (Tata Memorial Hospital & Cancer Research Institute) to the Department of Atomic Energy in 1962 was the next major milestone. The Tata Memorial Hospital and Cancer Research Institute merged as the two arms of the Tata Memorial Centre (TMC) in 1966 as a classic example of private philanthropy augmented by Government support with a mandate for Service, Education & Research in Cancer.
Every year nearly 30,000 new patients visit the clinics from all over India and neighboring countries. Nearly 60% of these cancer patients receive primary care at the Hospital of which over 70% are treated almost free of any charges. Over 1000 patients attend the OPD daily for medical advice, comprehensive care or for follow-up treatment. During the year 2003, over 20,000 new cases were registered in addition to over 13,000 Referral Cards issued for only special investigations. Nearly 8500 major operations are performed annually and 5000 patients treated with Radiotherapy and Chemotherapy annually in multi-disciplinary programmes delivering established treatments. At the TMH, Evidence Based Medicine is the keystone of our endeavor. Apart from the patient care and service, clinical research programmes and randomized trials contribute increasingly to improved delivery of care and highest standards of work ethics. Surgery remains the vital form of treatment along with radiation therapy and chemotherapy. The strategies for early diagnosis, treatment management, rehabilitation, pain relief and terminal care have been established in a comprehensive and multidisciplinary approach for a total cancer care programme. Many advances have taken place in every specialty. In surgery, concepts have changed taking into account the biology of cancer. Radical surgeries have yielded place to more conservative surgery with the very important objective of quality of life, conserving function and organ without compromising overall survival outcomes. Radiation therapy has also made rapid advances with high technology, precision, computerization and newer isotopes for therapy. Chemotherapy has played a very major role, with new drugs and clinical protocols investigated in clinical trials. The TMH was the first Centre in the country to initiate Bone Marrow Transplant in 1983. This has been possible due to better total supportive care using newer antibiotics, nutritional, blood transfusion support and nursing. Another important area of progress over the last few years has been radiological imaging techniques using ultrasound, CT scanners, MRI and more dynamic real-time nuclear medicine scanning and the PET Scan. A "first in India" PET CT scanner has been procured to make this cutting edge technology available for cancer management. Pathology has progressed from basic histopathology to molecular pathology with emphasis on predictive assays for identifying the high risk prognostic factors. Groundwork and processing for NABL accreditation is underway. In an effort to provide access to patients and their families who lack access or the means to visit the hospital, TMH has started an initiative to provide an online expert opinion through Navya.